All News

RA: total comorbidity count ≤1 (vs ≥ 2) predicts LDA/Rem @6 months ttmt [OR 4.1 p=0.005], while RDCI=0 (vs. ≥ 1) predicts HAQ improvement ≥0.25 [OR 2.6 p=0.046] Basal predictors of D2TRA: RDCI≥ 1(vs. 0) [OR 3.3 -p = 0.024], female sex and age #OP02999 @Rheumnow #EULAR2021 https://t.co/wc16oCKcix
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2021 key note speaker, Mark Pollock, is a model of resiliency after blindness and later, a spinal cord injury. "Sometimes we have the luxury of choosing our challenges and sometimes the challenges choose us." @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Poster from Cohen et al #POS0220 at #EULAR2021 No new safety signals in UPA treated RA patients in 4.5 years of SELECT clinical trial data. @RheumNow https://t.co/Q48ZaUee8q
Dr. Rachel Tate uptoTate ( View Tweet)
ASTERA phase 3 analysis: NTK leads to decline of disease activity in AS pts irrespectively of sacroiliitis on MRI. Abstract #OP0142 #EULAR2021 @RheumNow https://t.co/51f18728ZB https://t.co/qZcsMlKqbW

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Real world data from German AQUILA: SEC improved PsA dz activity in M & F pts. Female pts had higher dz burden prior to tx. #EULAR2021 Poster #POS0123 @RheumNow https://t.co/cNIN6yqN0j https://t.co/nPZLDztxQP

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Phase 2 Deucravacitinib, oral, selective TYK2i results: Analyses confirmed the efficacy of deucravacitinib vs PBO across TNFi & body weight subgroups. Safety profile similar to that found in PsO trials. Abstract #OP0227 #EULAR2021 @RheumNow https://t.co/BBvn5MaXPp https://t.co/jWFhpmkuC5

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
KEEPsAKE 2 results: RZB showed greater improvements in signs & symptoms of PsA vs PBO, met all primary/secondary endpoints, & was well tolerated in Bio-IR or csDMARD-IR pts. Safety profile consistent w/ PsO trials. Abstract #OP0228 #EULAR2021 @RheumNow https://t.co/jsF2JVTupg https://t.co/oiZWZ7Pkf2

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
GRAPPA 2021 treatment update highlights! ▶️Domain-specific tx choices ▶️Uveitis & IBD added ▶️ IL17i, IL23i, & JAKi strongly recommended in multiple domains ▶️PDE4i recs for dactylitis, enthesitis, & nail PsO ▶️Against IL6i #OP0229 #EULAR2021 @RheumNow https://t.co/5KFQu7myPO https://t.co/R9YSZBwFDh

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
COSMOS study results: GUS 100 mg Q8W showed ⬆️ACR20 vs PBO at W24; results of prespecified sensitivity and subgroup analyses were consistent. Safety profile consistent with PsO & biologic-naïve PsA pts. Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/CFN1MHB9yv https://t.co/BOZqyqaHPe

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
The Association of Psoriatic Arthritis abstract #OP0219 showed no clinically relevant ^ in mortality rate observed in PsA patients between 2003-2018. Mortality trends were similar to those in the general population. #EULAR2021 @RheumNow https://t.co/c45XBLvWrz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Data from 5 Nordic registries cohorts in #OP0222: incidence of ILD is 🔽in bDMARD treated PsA vs. RA pts, irrespective of co-medication with MTX. I wonder about evolving dx/seropositivity in pts w/ respect to ILD. #EULAR2021 @RheumNow https://t.co/0qFuXcPhmO https://t.co/gTUUtw80Lv

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021 https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK

Links:

Dr. John Cush RheumNow ( View Tweet)
Abstract #POS0296: real-world bDMARD dosing in axSpA and PsA: TNFi are used in approved dosing for most pts, but, non-TNFi-bDMARDs were often used in higher doses, corresponding to increased PsO dosing. #EULAR2021 @RheumNow https://t.co/7Br5UWtHJo https://t.co/UC4UYQpxml

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Would you take an SLE patient off of HCQ after 15 years of use seeing this data? @rheumnow @Lupusreference @LupusDocLim @Lupusdoc1 @LupusMD

k dao KDAO2011 ( View Tweet)

Per Dr. Dorner: women have higher rates of HCQ assc cardiac conduction abnormalities... not sure why... maybe because we prescribe this drug more in women? maybe because they have small volume of distribution than men? maybe women metabolize the medicine differently than men? https://t.co/X9YYJG3Zf0
k dao KDAO2011 ( View Tweet)
oh... and this from Ernest Choy and Clive Kelly. Combination therapy with anti-IL-6/anti-fibrotics for RA-ILD? 👀 OP0124 #EULAR2021 @RheumNow https://t.co/oaGjRgkq0x
David Liew drdavidliew ( View Tweet)
Nintedanib stalls *progressive fibrosing* RA-ILD (including across CRP and steroid subgroups). Presuming you can tolerate it, maybe there's something we can do for your RA-ILD now, apart from just controlling your arthritis! subanalysis from INBUILD #EULAR2021 @RheumNow https://t.co/hJCd37oRqK
David Liew drdavidliew ( View Tweet)
Clever from @DanielAletaha's group, asking: have trial patients really been MTX-optimised pre-enrollment? Placebo arm data from bDMARD trials x2: MTX continuation ACR20 w16: 25% v 12% (MTX works!) Should clinical trials have mandatory run-in periods? OP0127 #EULAR2021 @RheumNow https://t.co/Sx3IKOVKB6
David Liew drdavidliew ( View Tweet)
I'm not always a 'What Is New' session kind of guy, but given that it's Maria Cid introducing the always insightful @Sarah_L_Mackie on GCA I'll happily join the other 1012 viewers at #EULAR2021 tuning in! (So far, definitely and elegantly worth it.) @RheumNow https://t.co/kHOus21T1z
David Liew drdavidliew ( View Tweet)
After many years without love, RA-ILD therapy seems like it's on the move. MUC5B aside, we've seen abstracts at #EULAR2021 about: - tofacitinib (OP0125) - abatacept (POS0513) - rituximab (POS0645) - nintedanib (below) I discuss it a bit for @RheumNow: https://t.co/nk87kfjacb https://t.co/EjNbA2oLWs

Links:

David Liew drdavidliew ( View Tweet)

×